Calcimimetic Agents: Small organic molecules that act as allosteric activators of the calcium sensing receptor (CaSR) in the PARATHYROID GLANDS and other tissues. They lower the threshold for CaSR activation by extracellular calcium ions and diminish PARATHYROID HORMONE (PTH) release from parathyroid cells.Hyperparathyroidism, Secondary: Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY.Naphthalenes: Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics.Parathyroid Hormone: A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates.Receptors, Calcium-Sensing: A class of G-protein-coupled receptors that react to varying extracellular CALCIUM levels. Calcium-sensing receptors in the PARATHYROID GLANDS play an important role in the maintenance of calcium HOMEOSTASIS by regulating the release of PARATHYROID HORMONE. They differ from INTRACELLULAR CALCIUM-SENSING PROTEINS which sense intracellular calcium levels.Aniline CompoundsParathyroid Glands: Two pairs of small oval-shaped glands located in the front and the base of the NECK and adjacent to the two lobes of THYROID GLAND. They secrete PARATHYROID HORMONE that regulates the balance of CALCIUM; PHOSPHORUS; and MAGNESIUM in the body.Hyperparathyroidism: A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.DiethylaminesCalcium: A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.Hypocalcemia: Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed)Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.Parathyroidectomy: Excision of one or more of the parathyroid glands.Uremia: A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.Hypercalcemia: Abnormally high level of calcium in the blood.Calcitonin: A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults.Nephrectomy: Excision of kidney.Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.Calcitriol: The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption.Phosphates: Inorganic salts of phosphoric acid.Names: Personal names, given or surname, as cultural characteristics, as ethnological or religious patterns, as indications of the geographic distribution of families and inbreeding, etc. Analysis of isonymy, the quality of having the same or similar names, is useful in the study of population genetics. NAMES is used also for the history of names or name changes of corporate bodies, such as medical societies, universities, hospitals, government agencies, etc.Calcium Channel Blockers: A class of drugs that act by selective inhibition of calcium influx through cellular membranes.Drug Information Services: Services providing pharmaceutic and therapeutic drug information and consultation.National Library of Medicine (U.S.): An agency of the NATIONAL INSTITUTES OF HEALTH concerned with overall planning, promoting, and administering programs pertaining to advancement of medical and related sciences. Major activities of this institute include the collection, dissemination, and exchange of information important to the progress of medicine and health, research in medical informatics and support for medical library development.Granuloma, Giant Cell: A non-neoplastic inflammatory lesion, usually of the jaw or gingiva, containing large, multinucleated cells. It includes reparative giant cell granuloma. Peripheral giant cell granuloma refers to the gingiva (giant cell epulis); central refers to the jaw.Rickets: Disorders caused by interruption of BONE MINERALIZATION manifesting as OSTEOMALACIA in adults and characteristic deformities in infancy and childhood due to disturbances in normal BONE FORMATION. The mineralization process may be interrupted by disruption of VITAMIN D; PHOSPHORUS; or CALCIUM homeostasis, resulting from dietary deficiencies, or acquired, or inherited metabolic, or hormonal disturbances.Mandibular DiseasesFibrous Dysplasia, Monostotic: FIBROUS DYSPLASIA OF BONE involving only one bone.Paraneoplastic Syndromes: In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.Maxillary DiseasesLipid Metabolism Disorders: Pathological conditions resulting from abnormal anabolism or catabolism of lipids in the body.Calcium Metabolism Disorders: Disorders in the processing of calcium in the body: its absorption, transport, storage, and utilization.Minerals: Native, inorganic or fossilized organic substances having a definite chemical composition and formed by inorganic reactions. They may occur as individual crystals or may be disseminated in some other mineral or rock. (Grant & Hackh's Chemical Dictionary, 5th ed; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)Substance Abuse Treatment Centers: Health facilities providing therapy and/or rehabilitation for substance-dependent individuals. Methadone distribution centers are included.Substance-Related Disorders: Disorders related to substance abuse.Residential Treatment: A specialized residential treatment program for behavior disorders including substance abuse. It may include therapeutically planned group living and learning situations including teaching of adaptive skills to help patient functioning in the community. (From Kahn, A. P. and Fawcett, J. Encyclopedia of Mental Health, 1993, p320.)Phosphorus Metabolism Disorders: Disorders in the processing of phosphorus in the body: its absorption, transport, storage, and utilization.Blood Pressure: PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS.Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.Drug Repositioning: The deliberate and methodical practice of finding new applications for existing drugs.Drug Approval: Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.Transducers: Any device or element which converts an input signal into an output signal of a different form. Examples include the microphone, phonographic pickup, loudspeaker, barometer, photoelectric cell, automobile horn, doorbell, and underwater sound transducer. (McGraw Hill Dictionary of Scientific and Technical Terms, 4th ed)GeorgiaGeorgia (Republic)Prostatectomy: Complete or partial surgical removal of the prostate. Three primary approaches are commonly employed: suprapubic - removal through an incision above the pubis and through the urinary bladder; retropubic - as for suprapubic but without entering the urinary bladder; and transurethral (TRANSURETHRAL RESECTION OF PROSTATE).Radiotherapy, Computer-Assisted: Computer systems or programs used in accurate computations for providing radiation dosage treatment to patients.Prostatic Neoplasms: Tumors or cancer of the PROSTATE.Urology: A surgical specialty concerned with the study, diagnosis, and treatment of diseases of the urinary tract in both sexes, and the genital tract in the male. Common urological problems include urinary obstruction, URINARY INCONTINENCE, infections, and UROGENITAL NEOPLASMS.Radiotherapy, Image-Guided: The use of pre-treatment imaging modalities to position the patient, delineate the target, and align the beam of radiation to achieve optimal accuracy and reduce radiation damage to surrounding non-target tissues.Therapeutic Equivalency: The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease.Granulocyte Colony-Stimulating Factor: A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.

Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: analysis after a year with cinacalcet. (1/36)

INTRODUCTION: The most common cause of hypercalcemia in patients with transplanted kidneys is persistent hyperparathyroidism, which presents in 10%-30% of patients with functioning renal grafts. In these patients, the treatment of vitamin D-resistant hyperparathyroidism traditionally required parathyroidectomy. Calcimimetic agents represent a new therapeutic alternative; they inhibit parathyroid hormone (PTH) secretion, increasing the sensitivity of the calcium-sensitive receptor in the parathyroid gland. The objective of this study is to evaluate the efficacy of cinacalcet in renal transplant patients with persistent hyperparathyroidism. METHODS: Cinacalcet 30 mg/day was prescribed to 17 renal transplant patients (6 women, 11 men) with a mean age of 49 years and hypercalcemia secondary to persistent hyperparathyroidism. The treatment started 58.17 +/- 35.16 months posttransplant, with 1 year of follow-up. RESULTS: Calcium in serum fell from 10.5 +/- 0.74 to 9.4 +/- 0.84 mg/dL (p<0.001), whereas phosphorous levels were not significantly altered. The fall in PTH was from 204.79 +/- 78 to 148.55 +/- 56 pg/mL (p<0.011). Kidney function remained stable, and immunosuppressant drug levels remained unchanged. The dose of cinacalcet was increased to 60 mg in 2 patients. No significant adverse effects were described, and none of the patients had to suspend the treatment. CONCLUSIONS: Calcimimetic agents represent a therapeutic alternative in transplant patients with persistent hyperparathyroidism, as they correct hypercalcemia and reduce PTH levels with no adverse effects on kidney function. Prospective, controlled studies should be designed to evaluate the long-term effects and evolution after suspension of the treatment.  (+info)

Vascular actions of calcimimetics: role of Ca(2)(+) -sensing receptors versus Ca(2)(+) influx through L-type Ca(2)(+) channels. (2/36)

 (+info)

Cinacalcet improves bone density in post-kidney transplant hyperparathyroidism. (3/36)

 (+info)

The calcium-sensing receptor and calcimimetics in blood pressure modulation. (4/36)

 (+info)

Functional expression of the extracellular calcium sensing receptor (CaSR) in equine umbilical cord matrix size-sieved stem cells. (5/36)

 (+info)

Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. (6/36)

 (+info)

Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. (7/36)

 (+info)

Regression of vascular calcification in a patient treated with cinacalcet: a case report. (8/36)

 (+info)

We demonstrate that systemic activation of the CaR with the type-II calcimimetic, cinacalcet, at doses producing physiologically relevant reductions in blood iCa2+ and PTH acutely increases blood pressure in both anesthetized uremic and nonuremic rats. The increase in blood pressure was mediated by vasoconstriction as evidenced by increases in resistance in vascular beds perfused by the carotid, mesenteric, and hindlimb systemic arteries. Acute increases in blood pressure produced by i.v. infusion of cinacalcet in anesthetized rats were similar to those produced by another type-II calcimimetic, R-568, administered s.c. in conscious telemetry-instrumented rats (Odenwald et al., 2006), thus, acute increases in blood pressure may represent a class effect of calcimimetic agents in the rat.. Although, in previous studies, the mechanism responsible for acute increases in blood pressure produced by CaR activation with R-568 was not fully characterized, Odenwald et al. (2006) hypothesized that R-568 ...
Cinacalcet with NDC 47335-380 is a a human prescription drug product labeled by Sun Pharmaceutical Industries, Inc.. The generic name of Cinacalcet is cinacalcet.
A Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) When Two Different Vitamin D Regimens are Used in Subjects with Secondary Hyperparathyroidism of End-stage Renal Disease (ESRD). ...
With my PTH level over 80, I have started Cinacalcet 30mg today, so it will be interesting to see what happens to my PTH level and Calcium level. Interestingly
Sprawdź ile zapłacisz za lek Cinacalcet Hydrochloride w aptece, znajdź tańsze zamienniki leku. Określ swoje uprawnienia i sprawdź jakie zniżki Ci przysługują.
In this randomized, placebo controlled trial, patients on hemodialysis with moderate-to-severe secondary hyperparathyroidism were randomized to receive either cinacalcet or placebo. No difference was seen in the primary composite end point (time until death, myocardial infarction, hospitalization for unstable angina, heart failure, or a peripheral vascular event) between cinacalcet (48.2%) versus placebo (49.2%) HR 0.93; 95% CI, 0.85 to 1.02; P=0.11. Hypocalcemia and gastrointestinal adverse events were more common in patients on active treatment.. See the accompanying editorial ...
The 1K1C model is a severe, acute model of renal dysfunction which enables the activity of AMG 416 and cinacalcet to be investigated in the presence of the highly elevated levels of PTH and lack of kidney function typically seen in CKD-MBD patients receiving hemodialysis [1]. Due to its acute nature, the 1K1C model is not associated with the parathyroid gland hyperplasia seen in the rat 5/6 Nx uremic model and in dialysis patients with SHPT [9, 10]. However, it is an excellent model for assessing PTH-lowering activity in the background of severe kidney dysfunction. In this study, plasma PTH levels were significantly reduced by a single dose of either AMG 416 or cinacalcet. The effect of cinacalcet on PTH was of a lesser extent and shorter duration than seen with AMG 416, which maintained PTH lowering for more than 24 hr. The prolonged suppression of plasma PTH in the 1K1C model by AMG 416 is consistent with the pharmacokinetics (PK) observed for AMG 416 in normal rats and in different uremic ...
KDIGO Issues Updated Guidelines for Treatment of CKD-MBD In late June, the Kidney Disease Improving Global Outcomes (KDIGO) updated its Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). The update amends the 2009 KDIGO Clinical Practice Guideline and includes revised positions on standards of care for the treatment of secondary hyperparathyroidism ... Read More ». ...
A Multicenter Open-label Extension Study to Assess the Long-term Safety and Efficacy of KAI-4169 (also known as AMG 416) in the Treatment of Chronic Kidney Disease-Mineral and Bone Disorder in Patients with Secondary ...
CINACALCET (sin a CAL set) is used to treat patients with chronic kidney disease who are on dialysis. It is also used to treat high levels of calcium in the blood of patients with certain parathyroid gland problems.
Search for Cinacalcet Manufacturers / Generic Brands / Substitute / alternatives, prices, m.r.p. Order Medicines online on PillsBills.com. Free shipping all over India.
Background. Cinacalcet, a calcimimetic agent, is effective in treating both primary and secondary hyperparathyroidism. Because hyperparathyroidism induces mineralized bone loss, we investigated the effects of cinacalcet treatment on bone mineral density (BMD) in patients with secondary hyperparathyroidism due to chronic kidney disease.. Methods. Ten patients who were receiving haemodialysis and four patients, who had stage 4 chronic kidney disease participated and completed the multicentre, randomized, double-blind, placebo-controlled trials evaluating the safety and efficacy of cinacalcet for treating secondary hyperparathyroidism. The efficacy of cinacalcet was assessed by plasma intact parathyroid hormone (iPTH) levels. A dual energy X-ray absorptiometry was performed to measure the BMD of total proximal femurs and lumbar spine (L2-L4) before and after 26 weeks of treatment.. Results. Cinacalcet reduced iPTH from 912±296 to 515±359 pg/ml in haemodialysis patients and from 210±46 to 56±51 ...
The one-year mortality rate is consistently higher among PD patients than HD patients in Singapore; this may be due to the higher prevalence of significant comorbidities (e.g. ischaemic heart disease, cerebrovascular disease and peripheral vascular disease) among incident PD patients.(7) Studies have found that abnormal CKD-MBD parameters can affect all-cause mortality among patients on dialysis.(3-5,14,15) CKD-MBD is characterised by either one or a combination of the following items: (a) abnormalities in serum calcium, phosphorus or i-PTH levels, or vitamin D metabolism; (b) abnormalities in bone turnover, mineralisation, volume, linear growth or strength; and (c) the presence of vascular or other soft-tissue calcifications.(12) The complex relationship between abnormal CKD-MBD parameters and adverse clinical outcomes among incident PD patients has not been explored. Therefore, the present study was conducted to determine the prevalence of CKD-MBD among incident PD patients and examine the ...
Time to Primary Composite Endpoint (All-cause Mortality, Myocardial Infarction, Hospitalization for Unstable Angina, Heart Failure or Peripheral Vascular Event) [ Time Frame: From date of randomization until date of first confirmed primary composite endpoint event, assessed up to 5.4 years ...
Time to Primary Composite Endpoint (All-cause Mortality, Myocardial Infarction, Hospitalization for Unstable Angina, Heart Failure or Peripheral Vascular Event) [ Time Frame: From date of randomization until date of first confirmed primary composite endpoint event, assessed up to 5.4 years ...
Sensipar (Cinacalcet Hydrochloride) Drug Safety Communication - FDA Suspends Pediatric Clinical Trials After Report Of Death AUDIENCE Health Professional, Endoc
Cinacalcet therapy for achievement of the NKF/K-DOQITM clinical practice guidelines for bone and mineral metabolism in individuals under regular hemodialysis
Hypercalcemia of malignancy is the most common cause of hypercalcemia in hospitalized patients. It is associated with a poor prognosis, since it reflects an advanced cancer stage. Among all cancer in females, breast cancer is the most common malignancy, and it has the highest prevalence of hypercalcemia. Approximately 70% of patients with breast cancer have bone metastases and 10% of them will have hypercalcemia as a complication at some point in the disease. Herein, we report a 69-year-old female patient with metastatic breast cancer, who developed severe hypercalcemia in the course of her disease and was diagnosed with humoral hypercalcemia of malignancy (HHM). Intense hydration along with corticoisteroids and antiresorptive medication (calcitonin, bisphosphonates and denosumab) were administered to the patient. Despite the above treatment, serum calcium levels remain elevated and calcimimetic cinacalcet was added. Upon discontinuation of cinacalcet, calcium levels were raised and returned ...
Dr. Dehmel joins OxThera after serving as Executive Medical Director and Global Development Leader for Amgens calcimimetic franchise. He has extensive experience in the life science sector, having led Medical Affairs and Clinical Development teams responsible for drugs in Diabetes and End Stage Renal Disease. Bastian brings extensive experience in working with global regulatory agencies and was responsible for FDA and EMA approval of etelcalcetide, and more recently for the orphan pediatric drug approval of cinacalcet by EMA ...
Generic for mimpara (cinacalcet) is used for treating hyperparathyroidism. Order more than 10 tablets at our pharmacy and save your money.
Amgen (NASDAQ AMGN) today announced top-line results of the Phase 3 EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which ev
Chronic renal failure is almost always associated with secondary uraemic hyperparathyroidism. Action should be taken as early as possible to avoid it or reduce its severity in patients with chronic kidney disease (CKD). Over the last decade, the most effective way of achieving this has been defined as therapy with active vitamin D derivatives. However, the so‐called non‐hypercalcaemic vitamin D derivatives, which are said to be superior, have not met our expectations so far. In contrast, calcimimetic agents, the new class of compounds that act specifically on the calcium‐sensing receptor, are very promising for the treatment and prevention of hyperparathyroidism. CKD is associated with disturbances in calcium, phosphate, and vitamin D metabolism that occur early in the course of renal disease. In most patients, these disturbances lead to secondary hyperparathyroidism and osteitis fibrosa or associated, more complex, skeletal lesions. Here, we focus on recent advances in the prevention ...
Paricalcitol allowed the achievement of target parathyroid hormone levels better than cinacalcet in patients with secondary hyperparathyroidism (SHPT), a complication of chronic kidney disease (CKD). Both a vitamin D receptor activator such as paricalcitol and a calcimimetic such as cinacalcet effectively treat SHPT, which is characterized by elevated serum levels of intact parathyroid hormone (iPTH). Elevated iPTH levels can lead to skeletal and cardiovascular complications.
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
and expressly disclaims any duty to update information contained in this news release.. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us and our partners to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar ...
The calcium-sensing receptor (CASR) is the main calcium sensor in the maintenance of calcium metabolism. Mutations of the CASR, the G protein alpha 11 (GNA11) and the adaptor-related protein complex 2 sigma 1 subunit (AP2S1) genes can shift the set point for calcium sensing causing hyper- or hypo-calcemic disorders. Therapeutic concepts for these rare diseases range from general therapies of hyper- and hypo-calcemic conditions to more pathophysiology oriented approaches such as parathyroid hormone (PTH) substitution and allosteric CASR modulators. Cinacalcet is a calcimimetic that enhances receptor function and has gained approval for the treatment of hyperparathyroidism. Calcilytics in turn attenuate CASR activity and are currently under investigation for the treatment of various diseases. We conducted a literature search for reports about treatment of patients harboring inactivating or activating CASR, GNA11 or AP2S1 mutants and about in vitro effects of allosteric CASR modulators on mutated ...
UCL Discovery is UCLs open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.
CaSR signaling activity measured as the ratio between the level of phosphorylated and total p42/44 proteins. a: compared with the WT for both the Ca2+ concentra
In February, manufacturer Amgen announced that the FDA approved Parsabiv (etelcalcetide) for secondary hyperparathyroidism in patients with chronic kidney disease (CKD) on hemodialysis. Secondary hyperparathyroidism is a condition that lowers calcium levels, causing your parathyroid glands to overproduce the
Hypercalcemia of malignancy is the most common cause of hypercalcemia in hospitalized patients. It is associated with a poor prognosis, since it reflects an advanced cancer stage. Among all cancer in females, breast cancer is the most common malignancy, and it has the highest prevalence of hypercalcemia. Approximately 70% of patients with breast cancer have bone metastases and 10% of them will have hypercalcemia as a complication at some point in the disease. Herein, we report a 69-year-old female patient with metastatic breast cancer, who developed severe hypercalcemia in the course of her disease and was diagnosed with humoral hypercalcemia of malignancy (HHM). Intense hydration along with corticoisteroids and antiresorptive medication (calcitonin, bisphosphonates and denosumab) were administered to the patient. Despite the above treatment, serum calcium levels remain elevated and calcimimetic cinacalcet was added. Upon discontinuation of cinacalcet, calcium levels were raised and returned ...
Looking for online definition of nutritional secondary hyperparathyroidism in the Medical Dictionary? nutritional secondary hyperparathyroidism explanation free. What is nutritional secondary hyperparathyroidism? Meaning of nutritional secondary hyperparathyroidism medical term. What does nutritional secondary hyperparathyroidism mean?
Secondary hyperparathyroidism is characterized by pronounced parathyroid gland hyperplasia resulting from end-organ resistance to parathyroid hormone (PTH). The consequent hypersecretion of PTH depresses calcium levels.
Secondary Hyperparathyroidism Pipeline Review, H1 2017, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P5
Generic for sensipar is used for treating overactive parathyroid gland. Order 30mg and 60m dosages at InternationalDrugMart and save up to $226.64
The objective of the study was to determine whether the use of cinacalcet in patients undergoing hemodialysis would reduce the rates of death and major cardiovascular events, including myocardial infarction, hospitalization for unstable angina, heart failure and peripheral vascular events, all of which were considered endpoints for the study.. "The burden of hemodialysis treatment is considerable, and most patients take several prescription medications, often several times per day," Chertow said. "Cinacalcet is not a perfect drug. It has been shown to be safe and the gastrointestinal side effects are not prohibitive, but when someone is taking 20 pills a day, it is difficult to justify the 21st unless it makes an important difference.". The trial, which was originally designed to last four years, was extended to nearly five and a half years in an attempt to reach the required number of endpoints. Between Aug. 22, 2006, and Jan. 31, 2008, researchers recruited 3,883 patients on hemodialysis with ...
Calcimimetic Agents (1) • Small organic molecules that act as allosteric activators of the calcium sensing receptor (CaSR) in the PARATHYROID GLANDS and other tissues. They lower the threshold for CaSR activation by extracellular calcium ions and diminish PARATHYROID HORMONE (PTH) release from parathyroid cells. MeSH. Calcineurin Inhibitors (4) • Compounds that inhibit or block the PHOSPHATASE activity of CALCINEURIN. MeSH. Calcium Antagonists, Exogenous (0) see Calcium Channel Blockers. Calcium Channel Agonists (8) • Agents that increase calcium influx into calcium channels of excitable tissues. This causes vasoconstriction in VASCULAR SMOOTH MUSCLE and/or CARDIAC MUSCLE cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture. MeSH. Calcium Channel Blockers (117) • A ...
Secondary Hyperparathyroidism - Pipeline Insight, 2017 is a market research report available at US $1250 for a Single User PDF License from RnR Market Research Reports Library.
Hi! Im still very new here! i have Hashimotos and saw an endocrinologist for first time in Jan 16. He tested my PTH and calcium, VIt D etc and i was found to have slightly elevated PTH with low Vit...
Study Control of Mineral Metabolism (and other nonsense) flashcards from Caitlin Heim's class online, or in Brainscape's iPhone or Android app. ✓ Learn faster with spaced repetition.
The U.S. FDA has approved Parsabiv (etelcalcetide) to treat adult patients on dialysis and who experience secondary hyperparathyroidism.
Steaming bone disorder Addisons disease, Adrenal insufficiency, Adrenal failure, Adrenal cortical insufficiencyCentral retinitis, Degeneration of the retina, Retina degeneration, Hearing loss, Hypoacusis, , steaming bone disorder
There are many bone disorders that require clinical care by a physician or other healthcare professional. Listed in the directory below are some, for which we have provided a brief overview.. If you cannot find the information in which you are interested, please visit the Bone Disorders Online Resources page in this Web site for an Internet/World Wide Web address that may contain additional information on that topic.. ...
A type 1 excludes note is a pure excludes. It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as E83. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition ...
"Calcium-sensing receptor and calcimimetic agents". Kidney International. Supplement. 73: S52-8. PMID 10633465. Costanzo, Linda ... Nemeth EF, Shoback D (Jun 2013). "Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders". Best ...
Coburn JW, Elangovan L, Goodman WG, Frazaõ JM (Dec 1999). "Calcium-sensing receptor and calcimimetic agents". Kidney ... Nemeth EF, Shoback D (Jun 2013). "Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders". Best ...
"Definition of calcimimetic", Medicine.net (on line). Last editorial review: 4/8/2004. William G. Goodman, "Calcimimetic agents ... A calcimimetic is a pharmaceutical drug that mimics the action of calcium on tissues, by allosteric activation of the calcium- ... Calcimimetic use can have side effects. Common side effects include: nausea and vomiting, hypocalcemia, and adynamic bone ... Cinacalcet was the first calcimimetic to be approved. Cinacalcet mimics calcium at the parathyroid hormone receptor. This ...
Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials. Pediatr Nephrol. ... Geller et al21 treated patients successfully with cinacalcet, a calcimimetic agent. They hypothesized that medically induced ... Compassionate use of cinacalcet, a calcimimetic drug that suppresses PTH secretion and by reducing PTH-induced phosphate ... The most successful pharmacologic agents have been intralesional corticosteroid injections and systemic treatment with ...
The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) ... Calcimimetic Use in Familial Hypocalciuric Hypercalcemia-A Perspective in Endocrinology. J Clin Endocrinol Metab 2017; 102:3933 ... Wilhelm-Bals A, Parvex P, Magdelaine C, Girardin E. Successful use of bisphosphonate and calcimimetic in neonatal severe ...
Vasodilator Agents. Chelating Agents. Sequestering Agents. Calcium-Regulating Hormones and Agents. Calcimimetic Agents. Hormone ... Hypolipidemic Agents. Antimetabolites. Molecular Mechanisms of Pharmacological Action. Lipid Regulating Agents. ...
Calcimimetic Agents. Hormone Antagonists. Hormones, Hormone Substitutes, and Hormone Antagonists. Physiological Effects of ...
A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. ...
Pharmacologic: calcimimetic agents. Pregnancy Category: C. Indications. Secondary hyperparathyroidism in patients with chronic ... if treatment with a calcimimetic is indicated but cinacalcet is not suitable, and as long as the company provides the drug with ...
Calcimimetic Agents (1) • Small organic molecules that act as allosteric activators of the calcium sensing receptor (CaSR) in ... Complement Cytolysis Inhibiting Agents (0) see Complement Inactivating Agents. Complement Inactivating Agents (5) • Compounds ... Cardiac Depressants (0) see Anti-Arrhythmia Agents. Cardiotonic Agents (72) • Agents that have a strengthening effect on the ... Cariogenic Agents (2) • Substances that promote DENTAL CARIES. MeSH. Cariostatic Agents (10) • Substances that inhibit or ...
Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther. Nov 2005. 27(11):1725-51. ... Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal ...
Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther. Nov 2005. 27(11):1725-51. ... Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal ...
Coburn JW, Elangovan L, Goodman WG, Frazaõ JM (Dec 1999). "Calcium-sensing receptor and calcimimetic agents". Kidney ... Nemeth EF, Shoback D (Jun 2013). "Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders". Best ...
Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther. Nov 2005. 27(11):1725-51. ... Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal ... Which medications in the drug class Urinary Alkalinizing Agents are used in the treatment of Hypercalciuria? ...
Calcimimetic agents. Signs that indicate calcium levels are abnormal *Trousseaus sign: temporarily occlude arterial blood flow ... I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described. ...
Calcimimetic agents. Calcium and Magnesium Supplements. On the basis of the end users/applications, this Bone and Mineral ...
"Calcium-sensing receptor and calcimimetic agents". Kidney International. Supplement. 73: S52-8. PMID 10633465. Costanzo, Linda ... Nemeth EF, Shoback D (Jun 2013). "Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders". Best ...
Strippoli, G., Tong, A., Johnson, D., Schena, F., Craig, J. (2004). Antimicrobial agents to prevent peritonitis in peritoneal ... Meta-Analysis of Biochemical and Patient-Level Effects of Calcimimetic Therapy. American Journal of Kidney Diseases, 47(5), 715 ... Strippoli, G., Tong, A., Johnson, D., Schena, F., Craig, J. (2004). Antimicrobial agents to prevent peritonitis in peritoneal ... Campbell, D., Mudge, D., Craig, J., Johnson, D., Tong, A., Strippoli, G. (2017). Antimicrobial agents for preventing ...
The metabolism and disposition of calcimimetic agent cinacalcet HCl was examined after a single oral administration to mice, ... Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal ... ... These agents are potentially active in the urinary tract due to its elimination in an unaltered form by the renal route. This ... The ability of two structurally similar sulphur-containing drugs, the anti-rheumatic agent, D-penicillamine, and the mucoactive ...
Cinacalcet, a calcimimetic agent, is another option for lowering calcium for symptomatic patients with kidney involvement. This ... If the patient declines surgical intervention, a calcimimetic agent such as cinacalcet would be an appropriate therapy. ...
Frazao JM, Martins P, and Coburn JW (2002) The calcimimetic agents: perspectives for treatment. Kidney Int 61 (Suppl.): 149-154 ... Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, and Coburn JW (2000) A calcimimetic agent lowers plasma parathyroid ... 2005) Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and ... The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary ...
Sensipar® (cinacalcet) is the first oral calcimimetic agent approved by the FDA. for the treatment of SHPT in adult patients ... Etelcalcetide is a novel calcimimetic agent in clinical development for the treatment of SHPT in CKD patients on hemodialysis ... Etelcalcetide is a novel calcimimetic agent that suppresses the secretion of parathyroid hormone and is in clinical development ... If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously. ...
Amgen announces MAA submission to EMA for novel calcimimetic agent etelcalcetide Amgen today announced the submission of a ... If approved, etelcalcetide shall be the 1st calcimimetic agent that can be administered intravenously farmaciaunica.com/ ... Etelcalcetide shall be the 1st calcimimetic agent that can be administered intravenously.. ... opiniones-de-clientes . Etelcalcetide is a novel calcimimetic agent that suppresses the secretion of parathyroid hormone and is ...
"Definition of calcimimetic", Medicine.net (on line). Last editorial review: 4/8/2004. William G. Goodman, "Calcimimetic agents ... A calcimimetic is a pharmaceutical drug that mimics the action of calcium on tissues, by allosteric activation of the calcium- ... Calcimimetic use can have side effects. Common side effects include: nausea and vomiting, hypocalcemia, and adynamic bone ... Cinacalcet was the first calcimimetic to be approved. Cinacalcet mimics calcium at the parathyroid hormone receptor. This ...
The impact of calcimimetic agents on the use of different classes of phosphate binders: results of recent clinical trials. ... Which gadolinium-based contrast agents interfere with the colorimetric assays for calcium testing? ...
Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther. 2005 Nov; 27(11):1725-51. ... AIDS (Acquired Immunodeficiency Syndrome), pharmacists, Anti-HIV Agents, HIV Infections, AIDS-Related Opportunistic Infections ...
Sensipar/Mimpara is an oral calcimimetic agent approved for the treatment of secondary HPT in patients with CKD receiving ... Sensipar/Mimpara is the first oral calcimimetic agent approved for the treatment of secondary HPT in CKD patients receiving ...
... placebo-controlled trials evaluating the safety and effectiveness of the calcimimetic agent cinacalcet hydrochloride. ...
  • The ability to provide my patients with an intravenous calcimimetic and help ensure they receive the therapy they need is a tremendous milestone in the management of this frequently undertreated chronic progressive disease. (chemdiv.com)
  • We report the results of two identical randomized, double-blind, placebo-controlled trials evaluating the safety and effectiveness of the calcimimetic agent cinacalcet hydrochloride. (nih.gov)
  • A highly efficient and convenient procedure for the enantioselective synthesis of ( S )-Rivastigmine, a cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease, is accomplished by the treatment of versatile, readily accessible ( S )-(-)-2-methyl-2-propanesulfinamide with 3-hydroxyacetophenone. (scirp.org)
  • Treatment in the initial stage consists of a low-protein diet with restricted sodium intake and administration of hypotensive agents in the case of hypertension and of anabolic hormones, cardiac stimulants, and other drugs. (thefreedictionary.com)
  • In contrast, calcimimetic agents, the new class of compounds that act specifically on the calcium‐sensing receptor, are very promising for the treatment and prevention of hyperparathyroidism. (oup.com)
  • PTH and possibly some of its analogues are promising therapeutic agents for the treatment of postmenopausal or senile osteoporosis, and calcimimetic agents, which activate the CaSR, have provided new approaches for PTH suppression. (mhmedical.com)
  • The Academy continues to support CMS's implementation of section 1881(b)(14)(D)(ii) of the Social Security Act allowing for a payment adjustment and the proposed recalibration of the fixed dollar loss amounts "for high cost outliers due to unusual variations in the type or amount of medically necessary care, including variability in the amount of erythropoiesis stimulating agents (ESAs) necessary for anemia management. (eatrightpro.org)
  • Szczech LA. The impact of calcimimetic agents on the use of different classes of phosphate binders: results of recent clinical trials. (medscape.com)
  • A calcimimetic is a pharmaceutical drug that mimics the action of calcium on tissues, by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. (wikipedia.org)
  • This phenomenon is termed ''cell adhesion-mediated drug resistance'' (CAM-DR) and it is thought to be one of the major mechanisms by which MM cells escape the cytotoxic effects of therapeutic agents. (eurekaselect.com)
  • Sanofi-Aventis and Bristol-Myers Squibb against various generic drug manufacturers in litigation and several reexamination proceedings on patents covering Plavix®, a leading anti-thrombotic agent. (fitzpatrickcella.com)
  • Cinacalcet is a calcimimetic drug that allos-terically activates the calcium-sensing receptor expressed on the surface of the chief cells of the parathyroid gland. (ectrx.org)
  • Indeed, according to a survey fielded only last week (n=99), only one in five nephrologists has clinical experience with the drug, resulting in a 2% calcimimetic share overall. (spherixglobalinsights.com)
  • La combinación más efectiva fue el empleo de partículas de E. grandis, combinadas indistintamente con los cementos CPC40 o ARI50, adicionados con 3% de cloruro de calcio Resumen en inglés The most part of residues generated during wood mechanic processing remains unexplored for construction material non-structural compounds production. (worldwidescience.org)
  • In contrast, calcimimetic agents, the new class of compounds that act specifically on the calcium‐sensing. (oup.com)
  • New phosphate binding agents: ferric compounds. (unipd.it)
  • Calcimimetic agents increase the sensitivity of this receptor to cal. (drugline.org)
  • Cinacalcet is the first in a class of calcimimetic agents that increases the sensitivity of the calcium-sensing receptor to activation by extracellular calcium. (ahcmedia.com)
  • Overall, these findings provide new insight on the mechanisms of action of the calcimimetic R-568 in modulating vascular tone both in physiological and pathological conditions such as hypertension. (figshare.com)
  • SODIUM HYDROXIDE and potassium hydroxide are the most widely used caustic agents in industry. (nih.gov)
  • Calcimimetic R-568 vasodilatory effect on mesenteric vascular beds from normotensive (WKY) and spontaneously hypertensive (SHR) rats. (figshare.com)
  • A cooling sensation agent composition with a prolonged cool sensation effect is provided comprising at least one compound selected from the group consisting of. (patents.com)
  • Bars represent the mean±SEM for the antilipolytic effect in adipocytes exposed to the calcimimetic agent, as described in the Materials and methods section. (cdc.gov)
  • In the present study the vascular activity of calcimimetic R-568 was investigated in mesenteric vascular beds (MVBs) isolated from Spontaneously Hypertensive rats (SHR) and the relative age-matched Wistar-Kyoto (WKY) control rats. (figshare.com)
  • Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. (nih.gov)
  • These agents are potentially active in the urinary tract due to its elimination in an unaltered form by the renal route. (biomedsearch.com)